A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma

This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in participants with unresectable Malignant Pleural Mesothelioma (MPM) who have not received prior systemic therapy.
Per a business decision made by the Sponsor, participants who were randomized to amatuximab and were still on active treatment at the time of the protocol amendment may have consented to continue to receive weekly treatment with amatuximab until disease progression or intolerable toxicity at the discretion of the principal investigator. Participants randomized to placebo or who were in follow-up at the time of the amendment have been discontinued from the study.

开始日期2015-11-03

申办/合作机构

Morphotek, Inc.

NCT01521325

/ Completed临床1期

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non small cell lung cancer.

开始日期2011-09-01

申办/合作机构

Morphotek, Inc.

NCT01413451

/ Terminated早期临床1期IIT

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Background:
- Amatuximab is a cancer treatment drug that targets mesothelin. High levels of this substance are found on some kinds of tumor cells. Lab studies have shown that amatuximab helps the immune system to kill cells that have high levels of mesothelin. However, more research is needed to determine how safe and effective amatuximab is for treating tumors with high levels of mesothelin.
Objectives:
- To assess the safety and effectiveness of amatuximab in treating tumors with high levels of mesothelin.
Eligibility:
- Individuals at least 18 years of age who have a type of cancer that overexpresses mesothelin.
Design:
* Participants will be screened with a medical history and physical exam. They will also have blood tests and tumor assessment studies.
* Participants will have two intravenous doses of amatuximab several hours apart. Researchers will monitor them closely and do frequent blood draws. On the same day and also within 48 hours of the second dose, participants will have imaging studies. These studies will measure how well the amatuximab is working against the cancer.
* Participants will have a third imaging study of the cancer about 1 week after the infusions.
* Participants will have a followup visit 2 weeks after receiving amatuximab. This visit will require blood samples. Four weeks after receiving the drug, researchers will review patients symptoms or side effects. This interview can be done in person or by phone.

开始日期2011-07-12

申办/合作机构

National Cancer Institute

100 项与 Amatuximab 相关的临床结果

登录后查看更多信息

100 项与 Amatuximab 相关的转化医学

登录后查看更多信息

100 项与 Amatuximab 相关的专利（医药）

登录后查看更多信息

项与 Amatuximab 相关的文献（医药）

2026-03-01·NUCLEAR MEDICINE AND BIOLOGY

Mesothelin-targeted alpha therapy in PDAC with [225Ac]Ac-Macropa-PEG6-Amatuximab

Article

作者: Shabnam, Madeeha ; Shah, Syed Qaiser ; DeryaIlem-Ozdemir ; Santos-Oliveira, Ralph

Pancreatic ductal adenocarcinoma (PDAC) continues to be deadly and resistant to traditional treatments. Overexpressed in >80% of PDACs, mesothelin is an ideal target for antibody-based α-therapy. Actinium-225 (225Ac) produces high-LET α-particles leading to irreparable DNA damage, but its utility has been compromised by unstable chelation with traditional ligands. Here, we engineered a Macropa-enabled, site-specifically [²²⁵Ac]Ac-Macropa-PEG₆-Amatuximab, a radioimmunoconjugate against mesothelin. Conjugation and labeling were characterized by MALDI-TOF and SEC-HPLC. In vitro stability, immunoreactivity, and kinetics of binding were tested in mesothelin-positive AsPC-1 cells and subsequently in vivo biodistribution, dosimetry, and therapy in AsPC-1 xenograft-bearing nude mice. Conjugation had an average ratio of 3.6 ± 0.1 for chelator per antibody, radiolabeling efficiency of 96.3 ± 1.1%, and radiochemical purity ≥98%. The radioconjugate was >92% stable after 168 h in serum, with immunoreactivity (82.2 ± 2.8%) and affinity (Kd = 4.3 ± 0.9 nM). It exhibited specific, time-dependent internalization in AsPC-1 cells and minimal nonspecific uptake. In vivo, [²²⁵Ac]Ac-Macropa-PEG₆-Amatuximab exhibited prolonged circulation, specific tumor localization (3.9 ± 0.5 to 16.3 ± 2.1% ID/g, 1-168 h), and enhanced tumor-to-blood ratios (0.21-3.40). Blocking with unlabeled Amatuximab decreased tumor uptake by >60%. The tumor absorbed dose (1.82 ± 0.14 Gy/MBq) was 4-20-fold greater than doses to normal organs. Therapeutically, it caused dose-dependent tumor regression (TGI: 58% at 50 kBq; 92% at 150 kBq) and prolonged survival (>60 days vs. 0-1% in controls, p < 0.001). [²²⁵Ac]Ac-Macropa-PEG₆-Amatuximab is stable, selective, and therapeutically effective, demonstrating Macropa-based 225Ac chelation as a stable platform for targeted α-therapy of PDAC.

2025-06-01·European Journal of Nuclear Medicine and Molecular Imaging

Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography

Article

作者: Junbin Han ; Jinping Kong ; Yingfang He ; Ze Wang ; Yu Zhang ; Tingting Qing ; Fang Xie ; Tengxiang Chen

OBJECTIVES:

Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET).

METHODS:

VHH 269-H4 was obtained via immunization of llama using a fragment of MSLN from residue 360 to residue 597. S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was conjugated to VHH 269-H4 to yield precursor NOTA 269-H4 for radiolabeling. The chelator-to-VHH ratio was determined by mass spectrometry. The binding kinetics of VHH 269-H4 and NOTA 269-H4 were measured by surface plasmon resonance. Flow cytometry was carried out using the anti-mesothelin monoclonal antibody Anetumab to select MSLN-positive and MSLN-negative cell lines. After radiolabeling, the radiochemical purity and in vitro stability were tested by radio-thin-layer chromatography and size exclusion chromatography, respectively. A saturation binding assay was conducted to measure the dissociation constant (K_d) of [⁶⁸Ga]Ga-NOTA-269-H4. By mircoPET/CT imaging and biodistribution studies, the in vivo performances of the novel tracer were investigated in NCG mice bearing OVCAR-8, SKOV-3, or patient-derived xenografts.

RESULTS:

VHH 269-H4 targeting MSLN was obtained with a K_d value of 0.3 nM. After conjugation, approximately 27% and 3.2% of VHH were coupled to one and two NOTA chelators, respectively. This yielded precursor NOTA 269-H4 with a K_d value of 1.1 nM. The radiochemistry was accomplished with moderate radiochemical yields (34 ± 14%, n = 9, decay-corrected). [⁶⁸Ga]Ga-NOTA-269-H4 was obtained with high radiochemical purity (> 99%), and was stable after 90 min incubation at room temperature. The binding affinity of the radioligand towards MSLN was kept in the nanomolar range. Flow cytometry revealed that OVCAR-8 cells possess a high level of MSLN expression, while MSLN expression on SKOV-3 cells was negligible. Consistently, in microPET/CT imaging, [⁶⁸Ga]Ga-NOTA-269-H4 demonstrated clear tumor visualization using NCG mice bearing OVCAR-8 xenografts, but no radioactivity accumulation was observed in SKOV-3 xenografts, suggesting a high specificity of the tracer in vivo. In biodistribution studies, [⁶⁸Ga]Ga-NOTA-269-H4 displayed radioactivity accumulation of 2.93 ± 0.39%ID/g in OVCAR-8 xenografts at 30 min post-injection, and the highest tumor-to-blood ratio (~ 3) was achieved at 90 min post-injection. In NCG mice bearing patient-derived xenografts, [⁶⁸Ga]Ga-NOTA-269-H4 was able to noninvasively detect MSLN expression via microPET/CT imaging.

CONCLUSIONS:

To our knowledge, our studies achieved the first-time to non-invasively detect MSLN expression clearly using a single domain antibody fragment. To sum up, [⁶⁸Ga]Ga-NOTA-269-H4 is a highly promising PET probe to visualize MSLN expression in vivo and holds great potential to monitor MSLN expression during tumor development.

2024-12-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma

Article

作者: Feng, Maosen ; Li, Xiaoan ; Zheng, Xueting ; Yang, Xia ; Luo, Rui ; Shi, Mingsong ; Zou, Zhiyan ; Wang, Jiali ; Lu, Zhou ; Zhou, Yan ; Liang, Yuanyuan

Pancreatic ductal adenocarcinoma (PDAC) remains a significant clinical challenge, urgently requiring effective intervention strategies. In recent years, the application of radiopharmaceuticals has emerged as a promising modality for the accurate diagnosis and treatment of malignancies. Due to its high expression on pancreatic cancer cells, mesothelin (MSLN) has become an appealing target for radioimmunotherapy (RIT). In this study, we report the development of a novel radiotracer by conjugating amatuximab with zirconium-89 (⁸⁹Zr) to facilitate the non-invasive detection of MSLN expression. Immuno-positron emission tomography (immunoPET) imaging demonstrated a specific accumulation of ⁸⁹Zr-DFO- amatuximab in PANC-1-MSLN tumors. Subsequently, Lutetium-177 (¹⁷⁷Lu)-labeled amatuximab was utilized for MSLN- targeted radioimmunotherapy (RIT), resulting in a significant suppression of PANC-1-MSLN xenograft growth. Furthermore, in vivo studies indicated that ¹⁷⁷Lu-DOTA-amatuximab exhibited limited side effects. The development of ⁸⁹Zr/¹⁷⁷Lu-labeled amatuximab may provide novel insights into the formulation of precision diagnostic and therapeutic strategies for MSLN- overexpressing tumors, including PDAC.

项与 Amatuximab 相关的新闻（医药）

2026-06-09

·上海丰能数字健康技术研究院

【文献解读075】放射性核素靶向策略在胰腺癌诊疗中的研究进展

——基于《药学进展》2025年综述的深度解读引言：临床痛点与破局之匙胰腺癌，素有“癌王”之称，是恶性程度最高的消化道肿瘤之一。其临床挑战严峻：位置隐蔽，早期无明显症状，导致80%-90%的患者确诊时已属晚期，失去手术机会。5年生存率仅约13%，且对传统放化疗及免疫治疗的反应不佳。诊断层面，常规影像学（如CT、MRI）在区分肿瘤与炎症/纤维化、检测微转移灶方面存在局限；治疗层面，如何实现精准打击并降低对正常组织的损伤是核心难题。2025年9月，《药学进展》期刊发表了一篇题为《放射性核素靶向策略在胰腺癌诊疗中的研究进展》的综述（作者：徐珊珊、李晓阳、洪浩、何健等），系统梳理了核医学如何通过整合功能成像与分子靶向治疗，为突破这些困局提供新思路。本文将基于该综述，结合领域内关键数据与前沿进展，进行深度剖析。一、临床常规与局限：18F-FDG PET/CT的现状1.1 基于“瓦尔堡效应”的经典应用 18F-FDG PET/CT是目前肿瘤显像中最常用的放射性药物之一。其原理基于癌细胞异常活跃的糖代谢（瓦尔堡效应）。超过90%的胰腺导管腺癌（PDAC）因KRAS突变，导致葡萄糖转运体（GLUT1）和己糖激酶Ⅱ过表达，使得肿瘤对FDG的摄取显著高于正常胰腺组织。该技术能提供全身性的分子代谢信息，在以下方面具有重要价值：1）辅助初诊时CT/MRI难以确诊的病灶；2）评估远处转移；3）监测治疗反应及鉴别复发与纤维化。1.2 不可忽视的临床局限然而，18F-FDG PET/CT的特异性仅为65%左右。其主要局限在于无法有效区分PDAC与局灶性慢性胰腺炎，导致假阳性风险。此外，患者的高血糖状态也会显著影响检查的准确性。这些局限性催生了对新型、高特异性放射性示踪剂的迫切需求。二、靶向肿瘤抗原：直击癌细胞的“精准导弹” 近年来，针对肿瘤细胞表面特异性抗原的放射性核素药物研发进展迅速。这些“精准导弹”不仅用于诊断，更在治疗上展现出潜力。下表汇总了文献中提及的主要靶向肿瘤抗原的探针及其研究现状。靶点代表性放射性示踪剂主要进展与临床阶段主要挑战/备注 MUC1 64Cu-DOTA-C595 (诊断), 177Lu/213Bi-C595 (治疗) 90Y-放射性标记抗体联合小剂量化疗的临床研究显示对部分转移性患者可行。研究仍处初级阶段，需优化示踪剂以改善预后。间皮素 64Cu/89Zr/111In-抗MSLN抗体, α核素标记物多种核素标记的抗体在临床前及早期临床中显示优异显像；α核素治疗潜力良好。存在肝生理性摄取，可能干扰腹膜转移评估。需开发小型化抗体或预靶向策略。 PSMA 68Ga/18F-PSMA 68Ga-PSMA在胰腺病变中阳性预测率高于FDG，为PSMA阳性患者带来治疗新希望。临床研究多为单中心、小样本。需更大规模试验验证。 PD-1/PD-L1 64Cu/68Ga/89Zr-抗PD-1/PD-L1抗体在其他癌种中展现良好反应；是评估免疫疗法的重要工具。在胰腺癌中单独使用免疫疗法效果不佳，需开发联合策略的示踪剂。大多研究仍处临床前阶段。 KRAS 131I-ARS-1620 (靶向G12C突变) 在体外和体内试验中能够直接成像并筛选KRAS G12C突变体。 KRAS是胞内蛋白，传统核素载体难以有效结合及递送。需研发穿透性更强的新型药物。笔者认为，靶向肿瘤抗原的策略虽然前景广阔，但其核心挑战在于如何平衡靶点的肿瘤特异性与生理分布、如何克服肿瘤致密间质屏障对药物递送的阻碍。例如，虽然CA19-9是临床最常用的血清标志物，但作为核素靶点，其敏感性和特异性不足，且血液中高水平的抗原会形成“血池”背景，显著降低肿瘤/本底比值。未来的探针设计必须向小型化、高亲和力、药代动力学优化的方向发展。三、靶向肿瘤间质：攻破“纤维化堡垒”的新路径 PDAC的另一显著特征是其富含纤维结缔组织和炎症反应的致密间质，这构成了抵抗治疗的“堡垒”。靶向间质成分已成为创新的诊疗策略。3.1 成纤维细胞活化蛋白：诊断的“明星靶点” 成纤维细胞活化蛋白（FAP）在超过90%的PDAC相关成纤维细胞（CAF）中高表达，而在正常组织中几乎不表达。68Ga-FAPI-04 PET/CT在临床应用中展现出优异性能。关键数据显示，与18F-FDG相比，68Ga-FAPI-04在检测原发肿瘤、淋巴结及远处转移方面具有更高的敏感性和图像对比度，在临床分期上优势明显。尽管其治疗应用（如90Y-FAPI-04）报道尚少，但无疑是当前胰腺癌诊疗一体化研究中的热点。3.2 整合素αvβ6与纤维连接蛋白：临床前潜力初显整合素αvβ6在PDAC中的阳性率超过95%。68Ga标记的靶向肽和177Lu-DOTA-胱氨酸结肽在临床前模型中显示出高亲和力和特异性，证明了其在成像与治疗中的双重潜力。靶向纤维连接蛋白（FN）剪接区域的纳米体64Cu-NJB2，则能在小鼠模型中检测到早期胰腺上皮内瘤变，为极早期诊断带来了曙光。然而，这些探针的临床转化仍需大型、确证性的Ⅲ期临床试验数据支持。四、核心要点与未来展望诊疗一体化是核心方向：放射性核素靶向策略的核心价值在于将诊断（Diagnostics）与治疗（Therapy）无缝整合，实现真正的精准医疗。多种探针（如靶向MSLN、FAP的探针）已初步展现出“一药两用”的潜力。靶点选择决定应用场景：FAP、整合素αvβ6等间质靶点因其穿透性强，在早期诊断和分期中可能更具优势；而MUC1、MSLN等肿瘤细胞抗原则可能更适合作为治疗载体的靶向选择。临床转化仍是巨大瓶颈：绝大多数有前景的探针仍停留在临床前或早期（I/II期）临床阶段。从实验室到临床，需跨越药代动力学优化、毒性评估、生产标准化等多重障碍。未来突破在于“组合”与“智能”：未来的研究应聚焦于：a) 探针设计革新，如开发小型化、双特异性分子以提升穿透力与亲和力；b) 联合治疗策略，如探索放射增敏剂与核素治疗、化疗、免疫治疗的协同方案；c) 智能化技术赋能，利用人工智能预测最佳给药剂量，并基于患者的基因分型（如KRAS突变状态）定制个体化诊疗方案。综上所述，尽管前路挑战重重，但放射性核素靶向策略无疑为攻克胰腺癌这一“癌王”提供了极具希望的新武器。它不仅是影像技术的革新，更是治疗范式的演进。随着新型分子靶点探针的持续开发、多学科协作的深化以及临床转化步伐的加快，胰腺癌诊疗的精准化与个性化突破正逐渐从愿景走向现实。参考文献： [1] Stoop T F, et al. Pancreatic cancer. Lancet, 2025. [2] Siegel R L, et al. Cancer statistics, 2024. CA Cancer J Clin, 2024. [3] Hu Z I, O’Reilly E M. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol, 2024. [4] Wagle N S, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin, 2025. [5] Jhala N, et al. Molecular tests in pancreatic cancer. J Natl Compr Canc Netw, 2024. [6] Ying H, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev, 2025. [7] Hu S, et al. (18)F-FDG-PET/CT findings in pancreatic metastasis. Radiol Med, 2015. [8] Ferdinandus J, et al. Theranostics in oncology. Eur J Radiol, 2021. [9] Hu M, et al. Advances in preclinical research of theranostic radiopharmaceuticals. ACS Appl Mater Interfaces, 2025. [10] Bidkar A P, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res, 2023. [11] Wang J, et al. Preliminary study on the ability of the machine learning models based on (18)F-FDG PET/CT... Eur J Radiol, 2024. [12] Carlson D M, et al. Baseline characteristics and use of pretherapeutic 18F-fluorodeoxyglucose-PET for pancreatic cancer. J Am Coll Surg, 2024. [13] Suh H, et al. Mucins in pancreatic cancer. Am J Cancer Res, 2017. [14] Hull A, et al. Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer. EJNMMI Radiopharm Chem, 2023. [15] Picozzi V J, et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine. Eur J Cancer, 2015. [16] Liu D, et al. Mesothelin-associated anti-senescence through P53 in pancreatic ductal adenocarcinoma. Cancers (Basel), 2025. [17] Kobayashi K, et al. A novel PET imaging using 64Cu-labeled monoclonal antibody against mesothelin. J Immunol Res, 2015. [18] Lu Z, et al. Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in PDAC. Int J Pharm, 2024. [19] Wang X, et al. Construction and preclinical evaluation of 211At labeled anti-mesothelin antibodies. J Radiat Res, 2020. [20] Hung Y H, et al. Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance. Am J Cancer Res, 2024. [21] Hodolic M, et al. Safety and tolerability of 68Ga-NT-20.3 in patients with PDAC. Eur J Nucl Med Mol Imaging, 2021. [22] Pabst K M, et al. Detection of tumour heterogeneity... on [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT. Eur J Nucl Med Mol Imaging, 2024. [23] Puik J R, et al. 18F-prostate-specific membrane antigen PET/CT imaging for potentially resectable pancreatic cancer. Cancer Imaging, 2025. [24] Aziz M H, et al. Overexpression of the adhesion signaling pathway is linked to short-term survival in PDAC. Pancreatology, 2024. [25] Tsang K Y, et al. Development and characterization of an anti-cancer monoclonal antibody for treatment of human carcinomas. Cancers (Basel), 2022. [26] Schoffelen R, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer. Br J Cancer, 2013. [27] Hitchen N, et al. Recent advances in therapeutic targeting of the KRAS pathway in cancer. Pharmacol Ther, 2025. [28] Suyal C, et al. Structure-activity relationships of KRAS-G12D inhibitors for pancreatic cancer. Drug Discov Today, 2025. [29] Zhang Z, et al. Development and preclinical evaluation of radiolabeled covalent G12C-specific inhibitors. Mol Pharm, 2021. [30] Chen M H, et al. Cancer cell-intrinsic PD-1. Biomed Pharmacother, 2023. [31] Daunke T, et al. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of PDAC. Front Immunol, 2023. [32] van de Donk P P, et al. Molecular imaging to support cancer immunotherapy. J Immunother Cancer, 2022. [33] Burvenich I J G, et al. Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a. Theranostics, 2018. [34] Luo G P, et al. Roles of CA19-9 in pancreatic cancer. Biochim Biophys Acta Rev Cancer, 2021. [35] Poty S, et al. 89Zr-PET imaging of DNA double-strand breaks... in a mouse model of PDAC. Theranostics, 2020. [36] Zhu J, et al. In vivo PET imaging of EGFR expression: an overview of radiolabeled EGFR TKIs. Curr Top Med Chem, 2022. [37] Homedan A, et al. Protein-based radiopharmaceuticals that target fibroblast activation protein alpha. EJNMMI Radiopharm Chem, 2025. [38] Ganguly T, et al. Preclinical evaluation of 68Ga- and 177Lu-labeled integrin αvβ6-targeting radiotheranostic peptides. J Nucl Med, 2023. [39] Sachindra S, et al. SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-Integrin αvβ6 cystine knot peptide. Front Oncol, 2021. [40] Hu D Y, et al. Stromal fibronectin expression in patients with resected PDAC. World J Surg Oncol, 2019. [41] Jailkhani N, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci USA, 2019. [42] 黄敏. 靶向肿瘤代谢的新药研发：挑战与机遇. 药学进展, 2024. [43] 李顺尧, 等. 靶向肿瘤代谢酶小分子药物研究进展. 药学进展, 2024.

2026-04-24

·星狐说药

AACR 2026 深度洞察：MNC药物推荐

行业背景与战略评估基准 2026年美国癌症研究协会（AACR）年会的落幕，标志着全球肿瘤学研发管线进入了一个关键的战略转折点。过去数年中，大量的资本与临床资源被集中投入到少数几个热门靶点与机制中，例如PD-1/VEGF双特异性抗体、B7-H4抗体偶联药物（ADC）以及PRMT5 MTA协同抑制剂等 1。尽管这些领域在早期临床中展现了潜力，但极度拥挤的竞争格局（动辄数十个同类管线处于临床开发阶段）导致了严重的临床试验患者招募困难，并极大地压缩了药物未来的商业化利润空间与市场独占期。本报告基于对AACR 2026大会公开的数千份壁报（Poster）、摘要（Abstract）以及“突破性新药（New Drugs on the Horizon）”专场的深度数据挖掘与分析，甄选出10款由跨国制药巨头（MNC）主导开发的核心药物。这些药物的筛选严格遵循四个维度的标准：首先，药物必须由具备全球商业化能力的MNC主导或深度参与开发；其次，其在最新公开的有效性和安全性数据上，必须对现有的标准疗法（Standard of Care, SoC）具有革命性的优势；第三，其所处赛道的全球竞争格局必须呈现“蓝海”特征；这一评估旨在为临床研究者、行业分析师以及战略决策者提供未来三到五年内最具转化潜力和市场爆发力的靶点风向标。 1. IPN60300 – 益普生 (Ipsen)靶点机制与生物学逻辑整合素Alpha-2（Integrin alpha-2, ITGA2）是一种介导细胞与细胞外基质（ECM）相互作用的跨膜受体，其在多种侵袭性胃肠道肿瘤（如胰腺癌、胃癌和结直肠癌）的肿瘤基质和细胞表面高度过表达 10。历史上，科学界试图通过小分子拮抗剂或裸抗体来阻断整合素通路，但由于缺乏直接的细胞毒性杀伤机制，这些尝试大多以失败告终 12。益普生的IPN60300对该靶点进行了范式重构，将其作为ADC的抗原递送载体，通过与高亲和力抗体结合，将强效的拓扑异构酶I抑制剂（Exatecan，依喜替康）直接靶向输送至肿瘤微环境中 10。 AACR 2026 核心有效性与安全性数据在AACR 2026极为瞩目的“突破性新药（New Drugs on the Horizon）”专场中，益普生首次披露了IPN60300的临床前及早期转化医学数据 10。实验表明，该ADC对ITGA2具有极高的结合亲和力，且在内化后能够迅速释放毒性载荷。在高度侵袭性的胰腺癌和胃癌的异种移植模型中，IPN60300展现出了剂量依赖性的深度抗肿瘤活性，诱导了肿瘤的完全消退 10。同时，基因敲除（Knockout）实验证实，在ITGA2缺失的肿瘤模型中，该药物完全不产生细胞毒性，这极其严谨地验证了其“on-target”的高特异性，从而确保了对正常组织的保护 11。相对于标准疗法的临床优势晚期胰腺癌和胃癌的现有标准疗法主要依赖于全身性细胞毒化疗组合，这些疗法不仅客观缓解率低下，且伴随严重的全身性器官毒性。通过利用ITGA2这一在正常组织中低表达、在肿瘤基质中高表达的新型靶点，IPN60300成功绕过了传统化疗的耐药机制，同时也避开了HER2或TROP2等常见ADC靶点可能带来的靶向毒性重叠，为重度预处理的难治性胃肠道肿瘤患者打开了一个全新的高耐受性治疗窗口。全球竞争格局分析 ITGA2靶点的全球竞争格局呈现出极其罕见的“真空状态”。在卫材（Eisai）宣布终止其小分子整合素抑制剂E7820的开发后，IPN60300成为了全球唯一一款处于临床开发活跃期的ITGA2靶向资产 12。这种零竞争对手的临床格局赋予了益普生在这一生物标志物细分市场中无可争议的垄断潜力。 2. Invikafusp alfa (STAR0602) – 吉利德科学 (Gilead Sciences) / Marengo Therapeutics靶点机制与生物学逻辑免疫检查点阻断（ICB）疗法（如PD-1/PD-L1抑制剂）尽管具有划时代的意义，但其局限性日益凸显：绝大多数实体瘤患者最终会产生原发性或获得性耐药。传统的双特异性T细胞结合器（TCE）试图通过抗CD3抗体强制激活所有T细胞来克服耐药，但这不可避免地会引发严重甚至致命的细胞因子释放综合征（CRS）。作为由Gilead和Marengo深度合作开发的药物，Invikafusp alfa（STAR0602）采用了一种完全不同的生物学路径：它选择性地靶向胚系T细胞受体（TCR）变异体Vβ6和Vβ10，并将其与突变的人白细胞介素-2（IL-2）结构域融合 17。该药物通过非克隆性的TCR激活模式，选择性地扩增具有“记忆样效应表型”的特定T细胞亚群，使其能够深度浸润肿瘤，而不会触发广泛的全系统炎症风暴 17。 AACR 2026 核心有效性与安全性数据 AACR 2026年会上公布了START-001 I/II期临床试验的重磅更新数据。该研究纳入了肿瘤突变负荷高（TMB-H）或微卫星高度不稳定（MSI-H）的重度预处理患者（其中31%的患者接受过≥4线既往治疗，对PD-1/PD-L1已完全耐药） 19。临床疗效与安全性指标 Invikafusp alfa 单药治疗数据 (START-001) 靶病灶缩小患者比例 52% (15/29 可评估患者) 客观缓解率 (ORR) 21% (确认的部分缓解) 疾病控制率 (DCR) 83% 4/5级 TRAEs 或 ICANS 发生率 0% 在安全性方面，该药物表现出极为优异的耐受性。试验中未观察到任何免疫效应细胞相关神经毒性综合征（ICANS）、无4级治疗相关不良事件（TRAE），且无治疗相关死亡 18。仅有少数患者出现了3级CRS，但通过标准的支持性治疗（如皮质类固醇和托珠单抗）均得到了有效且迅速的控制 18。相对于标准疗法的临床优势对于已经对PD-1/PD-L1抑制剂产生耐药的TMB-H实体瘤患者而言，后续标准疗法的临床获益几乎可以忽略不计。Invikafusp alfa 的核心优势在于，它不依赖于失效的PD-1通路，而是通过激活全新的Vβ T细胞网络，重新构建了针对肿瘤的免疫识别和杀伤闭环。此外，其卓越的安全性特征使其成为理想的联合治疗骨干（Backbone），目前正与ADC药物Trodelvy在START-002试验中进行联合用药评估，极大地拓宽了其在难治性乳腺癌中的治疗潜力 21。全球竞争格局分析选择性Vβ TCR激活领域是一个极具技术壁垒的新兴赛道，目前由Marengo的STAR平台技术所主导。全球范围内，唯一一个采用类似Vβ激活机制的临床阶段竞品是益普生（Ipsen）的IPN01203 23。这意味着吉利德与Marengo仅面临1个直接临床竞争对手，符合严格的低竞争标准，使它们能够在不受同质化靶点内卷影响的情况下，从容确立该药物类别的监管与商业化标准。 3. IPN01203 (STAR0501) – 益普生 (Ipsen) / Marengo Therapeutics靶点机制与生物学逻辑与吉利德开发的Invikafusp alfa同源，IPN01203同样脱胎于Marengo Therapeutics的STAR平台，并由益普生获得了全球许可。IPN01203是一款首创（First-in-class）的多特异性融合蛋白，通过双重结合TCR和白细胞介素-15受体（IL-15R）通路，选择性地激活Vβ6和Vβ10 T细胞亚群 23。与STAR0602采用IL-2通路不同，IPN01203对IL-15R通路的特异性利用赋予了其截然不同的药代动力学特性和免疫启动能力。IL-15信号传导极大地促进了自然杀伤（NK）细胞和CD8+记忆T细胞的存活与增殖，这一机制专门为穿透和瓦解缺乏免疫细胞浸润的“冷肿瘤（Cold Tumors）”架构而设计 23。 AACR 2026 核心有效性与安全性数据在AACR 2026大会最具前瞻性的“突破性新药”会议上，益普生首次展示了IPN01203极具说服力的临床前及I期转化数据 24。数据确凿地证明，该分子能够在体内引发精确、泛肿瘤选择性的Vβ T细胞扩增。其免疫激活特征有效规避了通常导致严重细胞因子风暴的巨噬细胞过度激活现象。在多种实体瘤动物模型中，IPN01203成功动员了大量的肿瘤浸润淋巴细胞（TILs），在带来持久且深度的肿瘤消退的同时，在多种哺乳动物模型中保持了近乎完美的药物耐受性 25。相对于标准疗法的临床优势 IPN01203不仅与Invikafusp alfa一样具备克服PD-1耐药性的战略优势，其独特整合的IL-15R通路更是赋予了它在免疫微环境重塑上的独特潜力。传统的IL-2疗法（如阿地白介素）在临床应用中饱受毛细血管渗漏综合征的困扰，并且会非特异性地扩增具有免疫抑制作用的调节性T细胞（Tregs）。IPN01203通过将IL-15信号精准定向传递给Vβ T细胞，巧妙地绕过了Treg的激活网络，从而在肿瘤微环境中建立了一个更持久、更纯粹的免疫刺激状态，彻底剥离了历史细胞因子疗法伴随的严重不良反应。全球竞争格局分析选择性结合Vβ TCR变异体这一治疗策略高度专有化。如前所述，目前唯一存在的临床阶段竞品仅为吉利德合作的Invikafusp alfa 23。益普生在这一前沿生态基位中占据了事实上的双寡头地位，确保了其后续的临床验证能够直接转化为压倒性的市场份额，完全免受当前CD3双特异性抗体领域因靶点同质化而引发的价格战与患者入组危机。 4. Casdatifan (AB521) – 吉利德科学 (Gilead Sciences) / Arcus Biosciences靶点机制与生物学逻辑透明细胞肾细胞癌（ccRCC）的发生从根本上由von Hippel-Lindau（VHL）抑癌基因的失活驱动，这一基因突变导致缺氧诱导因子2-alpha（HIF-2α）在细胞内组成性、不受控制地积累。HIF-2α作为核心转录因子，驱动着庞大的促血管生成和促增殖基因网络（包括VEGF和AXL）27。尽管第一代HIF-2α抑制剂Belzutifan成功验证了这一靶点的可行性，但在后线治疗中，其存在靶点抑制不彻底和易产生耐药性的问题。Casdatifan在分子结构上进行了深度重构，旨在提供更优的药代动力学暴露量，对HIF-2α复合体实现更深度、更持续的抑制阻断 28。 AACR 2026 核心有效性与安全性数据 Arcus和Gilead在2026年肿瘤学会议周期（ASCO GU及AACR）分享了ARC-20研究I/Ib期的最新更新数据，充分印证了Casdatifan具备同类最佳（Best-in-class）的潜力。大会披露的全新生物标志物数据明确确立了血清促红细胞生成素（sEPO）抑制幅度与临床获益之间的强烈相关性，而sEPO正是HIF-2α活性的直接下游标志物 28。疗效评估指标 (ARC-20 临床试验) Casdatifan (100mg 每日一次队列) 确认的客观缓解率 (cORR) 45% 中位无进展生存期 (mPFS) 15.1 个月 18个月里程碑PFS率 (汇总分析) 43%相对于标准疗法的临床优势 Casdatifan的临床数据显著超越了唯一上市的HIF-2α抑制剂（Belzutifan）的历史与已发表基准。具体而言，在免疫治疗（IO）经治的晚期ccRCC患者中，Casdatifan 100mg队列实现了15.1个月的mPFS，这一生存获益几乎是Belzutifan在同等患者群体中已发表数据的两到三倍 28。在重度预处理的患者中取得45%的确认ORR，这标志着该药物对现有标准后线疗法（如序贯TKI或mTOR抑制剂）形成了降维打击，因为传统后线靶向药物不仅缓解率极低，且伴随着令人难以忍受的脱靶毒副作用 27。全球竞争格局分析由于靶向HIF-2α蛋白的PAS-B结构域需要极其复杂的结构化学设计，该靶点的研发壁垒极高，导致竞争格局异常精简。目前全球临床进展主要由已获批的Belzutifan（默沙东）占据先机，其他进入临床阶段的显著资产仅有NiKang Therapeutics的NKT-2152。随着诺华（Novartis）宣布终止其HIF-2α候选药物DFF332的开发 31，Casdatifan面临的活跃临床竞品仅剩1到2个。这为吉利德和Arcus在快速推进一线（1L）III期临床试验时，提供了极为宽广且缺乏干扰的商业化抢滩跑道 29。 5. Vepugratinib – 礼来 (Eli Lilly)靶点机制与生物学逻辑成纤维细胞生长因子受体3（FGFR3）的激活突变和基因融合是尿路上皮癌及其他多种实体瘤的核心致癌驱动因素。第一代泛FGFR抑制剂（例如厄达替尼，Erdafitinib）虽然成功靶向了这一通路，但存在一个致命的药理学缺陷：它们会不加区分地同时抑制FGFR1、FGFR2和FGFR4。其中，对FGFR1的抑制会严重破坏人体的磷酸盐稳态，引发严重的高磷血症、组织钙化和眼部毒性。这些靶向脱靶毒性迫使医生大幅降低给药剂量或频繁中断治疗，从而严重削弱了药物的临床疗效 32。Vepugratinib 是一种下一代、高度亚型选择性的FGFR3抑制剂，其设计初衷在于最大化肿瘤病灶处的靶点占有率，同时完全避开由FGFR1驱动的磷酸盐代谢通路。 AACR 2026 核心有效性与安全性数据在ESMO至AACR 2026期间释放的连续临床数据显示了Vepugratinib惊人的疗效潜力。整体评估队列中，该药物实现了29%的客观缓解率（ORR）32。最令人瞩目的是，Vepugratinib在之前已经对泛FGFR抑制剂（如Balversa）产生耐药并疾病进展的极高难度患者中，依然展示出了深度的临床活性——在7名此类难治性患者中，有3名取得了确认的疾病缓解 32。这有力地证明了Vepugratinib优越的治疗窗口（Therapeutic Window）允许临床给予足够高的剂量，以克服使第一代药物失效的获得性耐药突变。相对于标准疗法的临床优势通过将FGFR3的抗肿瘤疗效与FGFR1介导的全身毒性彻底解绑，Vepugratinib允许患者接受持续、高强度的靶点抑制治疗。患者无需再忍受频繁的停药、严苛的饮食限制以及与高磷血症相关的并发症。更重要的是，它能够挽救那些对现行标准疗法（泛FGFR抑制剂）已经失效的患者，这一特性填补了巨大的临床空白，代表了靶向治疗策略的重大演进。全球竞争格局分析开发高选择性FGFR3抑制剂在分子对接与药物化学层面面临巨大挑战，这直接限制了能够进入该赛道的玩家数量。目前，在高度选择性FGFR3领域，Vepugratinib唯一的主要临床阶段竞争对手是Tyra Biosciences开发的TYRA-300 32。在仅有1个直接临床竞争对手的环境下，礼来拥有不受束缚的发展轨迹，完全有能力重塑由FGFR3驱动的恶性肿瘤的标准治疗指南。 6. BMS-986365 (CC-94676) – 百时美施贵宝 (Bristol Myers Squibb)靶点机制与生物学逻辑转移性去势抵抗性前列腺癌（mCRPC）在接受标准雄激素受体通路抑制剂（ARPIs，如恩扎卢胺和阿比特龙）治疗后，最终都会产生耐药性。肿瘤细胞通过扩增AR基因，或在配体结合结构域（LBD）产生点突变，将原本的拮抗剂逆转为激动剂，从而继续驱动肿瘤生长。BMS-986365是一款首创的（First-in-class）、由Cereblon介导的异双功能靶向蛋白降解剂（PROTAC）33。与传统的小分子阻断剂不同，BMS-986365直接招募细胞自身的泛素-蛋白酶体系统，从物理层面上彻底摧毁野生型以及含有临床相关突变的雄激素受体蛋白，从根本上阻断AR驱动的转录活性 33。 AACR 2026 核心有效性与安全性数据在AACR 2026会议上，百时美施贵宝展示了极具说服力的临床数据。结果表明，BMS-986365在经过多线密集治疗的mCRPC患者群体中展现出高度的抗肿瘤活性。该降解剂成功克服了现有ARPI的耐药性，且疗效不受底层AR LBD突变状态的限制 34。同时，其安全性被证实是可控且耐受性良好的，成功避免了早期靶向蛋白降解剂令人担忧的广泛脱靶和系统性毒性 34。数据还初步显示，在未接受过化疗的（Chemo-naïve）患者中，其临床获益幅度甚至更大，这为其向更早期治疗线数（Front-line）的推进提供了强有力的证据支撑 34。相对于标准疗法的临床优势目前的ARPI标准疗法仅仅是通过竞争性拮抗起效；它们将致癌的AR蛋白完好无损地保留在细胞内，给了肿瘤充足的时间进行基因突变并最终击败药物。BMS-986365通过酶促降解机制，彻底移除了致癌信号传导所需的物理支架。这种绝对的靶点消除策略，为那些已经耗尽所有常规内分泌和抗雄激素疗法的晚期患者，提供了前所未有的生存获益优势。全球竞争格局分析前列腺癌中的靶向蛋白降解代表了一个高度复杂的技术前沿。该领域的临床阶段竞争格局异常稀疏。除了BMS-986365之外，临床上值得关注的AR降解剂主要包括ARV-766（近期被诺华引进许可）以及Bavdegalutamide (ARV-110) 35。在仅有2个临床阶段竞品存在的情况下，百时美施贵宝正处于一个竞争烈度极低的环境中，完美避开了传统小分子抑制剂赛道常见的红海厮杀。 7. Sigvotatug vedotin (SV / SGN-B6A) – 辉瑞 (Pfizer)靶点机制与生物学逻辑整合素Beta-6（Integrin beta-6, ITGB6）是一种细胞表面受体，在肿瘤的侵袭、转移以及肿瘤微环境中转化生长因子-beta（TGF-β）的激活中扮演着核心角色。ITGB6在许多与不良预后相关的恶性肿瘤（如非小细胞肺癌NSCLC和头颈部鳞状细胞癌HNSCC）中高频过表达，而在健康成人的正常组织中几乎不表达 36。Sigvotatug vedotin将靶向ITGB6的全人源单克隆抗体与经过充分临床验证的细胞毒载荷MMAE（单甲基奥瑞他汀E）结合在一起。当ADC被内化后，MMAE载荷释放并阻断微管聚合，迅速导致肿瘤细胞凋亡。至关重要的是，该机制伴随着强大的旁观者效应（Bystander effect），并能诱发免疫原性细胞死亡（ICD），从而改变肿瘤微环境，为后续的免疫细胞攻击做好铺垫 36。 AACR 2026 核心有效性与安全性数据辉瑞充分利用2026年的肿瘤学术会议平台，特别是在AACR及随后的ASCO上，重点强调了Sigvotatug vedotin广阔的临床前景，尤其是其与PD-1抑制剂帕博利珠单抗（Pembrolizumab）的联合用药潜力 37。公布的I期数据显示，SV显著提升了NSCLC和HNSCC患者队列的抗肿瘤活性。通过ITGB6受体靶向输送MMAE载荷，不仅安全、有效地瓦解了肿瘤实体，由此引发的免疫原性细胞死亡更是与免疫检查点阻断疗法产生了完美的协同效应，成功将免疫耐药或免疫抑制的“冷肿瘤”转化为高度响应的免疫敏感环境 36。相对于标准疗法的临床优势对于在一线免疫疗法和含铂化疗后出现疾病进展的NSCLC和HNSCC患者，其预后往往极为惨淡，且目前可用的靶向挽救选项寥寥无几。Sigvotatug vedotin提供了一种基于全新生物标志物导向的机制，能够将毁灭性的细胞毒载荷直接输送至肿瘤基质。其既作为直接的细胞毒性杀伤剂，又作为微环境免疫启动剂的双重威胁优势，使其在疗效上远胜于机制单一的传统后线挽救性化疗。全球竞争格局分析在广泛的ADC研发热潮中，ITGB6靶向的ADC领域仍是一片未被大规模开发的处女地。目前该靶点的主要竞争者是百奥赛图（Biocytogen）的BCG048（一款B7-H3 x ITGB6双抗ADC，在AACR 2026上以临床前/I期壁报形式展出），以及Sutro Biopharma处于临床前/I期阶段的STRO-006 12。由于仅有约1-2个处于早期临床阶段的活跃竞品，辉瑞的Sigvotatug vedotin在这一靶点领域牢牢占据着首创（First-in-class）以及临床进度最靠前的霸主地位。 8. PF-08052666 (MesoC2) – 辉瑞 (Pfizer) / Nona Biosciences靶点机制与生物学逻辑间皮素（Mesothelin, MSLN）是一种广为人知的肿瘤相关抗原，在间皮瘤、卵巢癌、肺癌和结直肠癌等多种实体瘤中高度上调。然而，历史上针对MSLN的药物开发（包括裸抗体以及早期如amatuximab和anetumab ravtansine等ADC）遭遇了滑铁卢。导致临床失败的罪魁祸首是“诱饵效应（Decoy Effect）”：肿瘤会将可溶性MSLN抗原脱落释放到血液中，这些游离抗原会在药物到达肿瘤表面之前提前与治疗抗体结合，从而中和并耗竭了药物 40。PF-08052666（MesoC2）是一款专门为克服这一致命屏障而工程化设计的下一代ADC。依托Harbour Mice平台，该单克隆抗体经过精密的亲和力调节，能够巧妙地忽略血液中的可溶性MSLN，同时对肿瘤细胞膜结合的MSLN保持极其强悍的结合和内化能力 41。此外，它偶联了高活性的拓扑异构酶I抑制剂（TOP1i），药物抗体比（DAR）高达8，确保了超强的杀伤效力。 AACR 2026 核心有效性与安全性数据在AACR 2026公布的临床前与I期转化医学数据（摘要编号324）证实，PF-08052666决定性地突破了传统MSLN靶向治疗的限制。体外分析明确显示，即使在存在高浓度生理相关可溶性MSLN的环境下，该ADC依然维持了毫不衰减的全额细胞毒性 41。在横跨卵巢癌、肺癌和结直肠癌的患者来源异种移植（PDX）模型中，PF-08052666的抗肿瘤表现将基于DM4毒素的传统MSLN ADC远远甩在身后。更重要的是，其新型连接子-载荷系统展示了强烈的“旁观者杀伤（Bystander killing）”效应，能够有效清剿肿瘤组织中不表达MSLN的异质性癌细胞 41。相对于标准疗法的临床优势通过彻底解决可溶性抗原的“诱饵”难题，PF-08052666让间皮素这一曾经折戟沉沙的靶点重获新生，展现出高度的临床可行性。其高达8的DAR值与TOP1i载荷的结合，相比于标准二线或三线化疗，提供了几何级数增长的局部肿瘤摧毁能力。其强大的旁观者效应对于结直肠癌和肺癌等高度异质性的实体瘤尤为关键，因为在这些肿瘤中，抗原在所有细胞上的均匀表达几乎是不可能的。全球竞争格局分析历史上MSLN靶向药物的连番失败导致大量制药公司撤出该领域，使得这一赛道的竞争格局被彻底清空。例如，Zymeworks近期就宣布终止了其MSLN导向的T细胞结合器ZW171的开发 43。随着老一代DM4 ADC被大面积放弃，采用高度工程化、搭载TOP1i载荷的下一代MSLN ADC的临床竞争环境极为宽松，活跃的临床竞品数量远低于3个 40。辉瑞通过战略性地引进这一资产，已然做好准备去主导一个经过验证但历史上极难攻克的价值高地。总结与战略建议 AACR 2026大会所披露的数据不仅展示了令人振奋的临床疗效，更勾勒出了跨国制药巨头（MNC）在肿瘤学战略布局上的明确演进路线。整个行业正在极其坚决地从拥挤的传统免疫检查点抑制剂和早期低效细胞毒载荷赛道中抽身撤离。本报告中深度剖析的8款核心资产，代表了未来五到十年肿瘤治疗发展的核心范式，其特征可归纳为以下三大趋势：载荷机制与成药模式的底层创新：传统的微管抑制剂时代正在退潮。诸如ABBV-319（引入糖皮质激素受体调节剂）和BMS-986365（靶向蛋白降解剂）等资产证明，重新定义化学载荷的作用机制，或通过蛋白质降解直接消除致病根源，能够产生远超传统受体拮抗或化疗毒素的临床收益。精准突破微环境与结构性物理屏障： PF-08052666（规避可溶性抗原陷阱）、IPN60300以及Sigvotatug vedotin（靶向基质整合素）的成功推进，突显了MNC将研发重点转向如何渗透、摧毁甚至利用肿瘤微环境中的物理与化学防御系统。高精度、去系统性毒副作用的免疫启动：第一代T细胞结合器（TCE）和细胞因子疗法因系统性毒性而受限。选择性Vβ TCR激活剂（Invikafusp alfa与IPN01203）的崛起，标志着免疫调节疗法进入了“精确制导”时代——在不引发细胞因子风暴的前提下，生成靶向的、具有记忆样效应的抗肿瘤免疫反应。对于临床试验的发起者、商业化决策团队以及生物医药投资者而言，这8款药物代表了高生物学确定性与低商业化摩擦力的完美交汇点。通过优先布局临床竞品少于3个的蓝海靶点，辉瑞、益普生、吉利德、艾伯维、礼来和百时美施贵宝等MNC正在构筑坚不可摧的护城河，这些资产无疑将在此后定义下一个十年全球肿瘤学临床实践的标准。Works cited ADC Pipeline Update: Four Antibody-Drug Conjugates Designated in February 2026 | PatSnap, accessed April 24, 2026, https://www.patsnap.com/resources/blog/articles/adc-pipeline-february-2026/ PD-1 & PD-L1 Inhibitors Market Growth Report 2031 - Mordor Intelligence, accessed April 24, 2026, https://www.mordorintelligence.com/industry-reports/pd1-and-pdl1-inhibitors-market PRMT5 inhibitors for MTAP-deleted cancers - PatSnap, accessed April 25, 2026, https://www.patsnap.com/resources/blog/articles/prmt5-inhibitors-for-mtap-deleted-cancers/ Biological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes - PMC, accessed April 25, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12910677/ Prifetrastat - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 25, 2026, https://synapse.patsnap.com/drug/41fbdd069c3544ac99cade2647811623 PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer | OncLive, accessed April 25, 2026, https://www.onclive.com/view/pf-07248144-plus-fulvestrant-is-safe-active-in-pretreated-er-her2-metastatic-breast-cancer NextCure joins the B7-H4 brigade | ApexOnco - Oncology Pipeline, accessed April 24, 2026, https://www.oncologypipeline.com/apexonco/nextcure-joins-b7-h4-brigade Pfizer dials down its atirmociclib ambitions | ApexOnco - Clinical Trials news and analysis, accessed April 24, 2026, https://www.oncologypipeline.com/apexonco/pfizer-dials-down-its-atirmociclib-ambitions KAT6 Inhibitors Market Report, Industry and Market Size & Revenue, Share, Forecast 2024–2030, accessed April 25, 2026, https://www.strategicmarketresearch.com/market-report/kat6-inhibitors-market Ipsen showcases transformative potential of early immuno-oncology ..., accessed April 25, 2026, https://www.ipsen.com/press-release/ipsen-showcases-transformative-potential-of-early-immuno-oncology-pipeline-at-aacr-3257884/ Abstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target | Cancer Research - AACR Journals, accessed April 25, 2026, https://aacrjournals.org/cancerres/article/86/7_Supplement/4444/779227/Abstract-4444-Integrin-alpha-2-ITGA2-is-a-novel AACR 2026 – conjugates remain centre stage | ApexOnco - Oncology Pipeline, accessed April 25, 2026, https://www.oncologypipeline.com/apexonco/aacr-2026-conjugates-remain-centre-stage Are Integrins Still Practicable Targets for Anti-Cancer Therapy? - MDPI, accessed April 24, 2026, https://www.mdpi.com/2072-6694/11/7/978 Glucocorticoids and Cancer | Request PDF - ResearchGate, accessed April 25, 2026, https://www.researchgate.net/publication/280536618_Glucocorticoids_and_Cancer Erwin R. Boghaert's research works | AbbVie and other places - ResearchGate, accessed April 25, 2026, https://www.researchgate.net/scientific-contributions/Erwin-R-Boghaert-2004365157 Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry - R Discovery, accessed April 25, 2026, https://discovery.researcher.life/article/novel-formats-of-antibody-conjugates-recent-advances-in-payload-diversity-conjugation-and-linker-chemistry/cdf858cac35f37e9a345dca25af219e1 Invikafusp alfa - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 25, 2026, https://synapse.patsnap.com/drug/f6af73a3d5364a368979e34456100bf8 Invikafusp Alfa Shows Promise in ICI-Resistant Solid Tumors | Targeted Oncology, accessed April 25, 2026, https://www.targetedonc.com/view/invikafusp-alfa-shows-promise-in-ici-resistant-solid-tumors START-001 Trial: Invikafusp Alfa Shows Promising Activity in ICB-Resistant, Antigen-Rich Solid Tumors - OncoDaily, accessed April 25, 2026, https://oncodaily.com/oncolibrary/start-001-trial Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Presentation - PR Newswire, accessed April 25, 2026, https://www.prnewswire.com/news-releases/marengo-to-share-updated-clinical-results-from-start-001-phase-12-clinical-trial-featuring-invikafusp-alfa-monotherapy-activity-in-pd1-resistant-tumors-at-upcoming-aacr-2025-clinical-plenary-oral-presentation-302437765.html MTS Trials - BreastCancerTrials.org, accessed April 25, 2026, https://www.breastcancertrials.org/bct_nation/mts/mtsResult.seam?brca=na&ar=na&pr=na&pi3k=na&er=na&her2=negative&pdl1=na&trialalertradius=null Browse Trials - BreastCancerTrials.org, accessed April 25, 2026, https://www.breastcancertrials.org/bct_nation/browse_trials.seam;jsessionid=32B0231D8DEF5218E7889A13295FD8E4?pageRecord=0&categoryString=All&cid=5565 Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026 - BioSpace, accessed April 25, 2026, https://www.biospace.com/press-releases/marengo-reports-late-breaking-initial-phase-2-clinical-results-from-invikafusp-alfa-plus-trodelvy-and-unveils-partnered-novel-ipn01203-star0501-star-program-in-phase-1-at-aacr-2026 IPN-60300 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 25, 2026, https://synapse.patsnap.com/drug/085e9cd47e3c427980dca6b28761cf9a H1 2024 results presentation - Ipsen, accessed April 25, 2026, https://www.ipsen.com/wp-content/uploads/2024/07/H1-2024-results-presentation.pdf Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR, accessed April 25, 2026, https://markets.businessinsider.com/news/stocks/ipsen-showcases-transformative-potential-of-early-immuno-oncology-pipeline-at-aacr-1035940074 Neil J. Shah's research works | Memorial Sloan Kettering Cancer Center and other places, accessed April 25, 2026, https://www.researchgate.net/scientific-contributions/Neil-J-Shah-2135849432 Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer - Investors & Media, accessed April 25, 2026, https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Presents-New-Data-for-its-HIF-2a-Inhibitor-Casdatifan-Which-Showed-Progression-Free-Survival-Beyond-One-Year-in-Late-Line-Kidney-Cancer/default.aspx Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs - Investors & Media, accessed April 25, 2026, https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Outlines-2026-Plans-for-Casdatifan-its-Potential-Best-in-Class-HIF-2a-Inhibitor-and-its-Inflammation-Programs/default.aspx Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event - BioSpace, accessed April 24, 2026, https://www.biospace.com/press-releases/arcus-biosciences-presents-new-data-for-its-hif-2a-inhibitor-casdatifan-and-discloses-first-inflammation-programs-at-investor-event Novartis calls time on TIM-3 and HIF2α | ApexOnco - Oncology Pipeline, accessed April 24, 2026, https://www.oncologypipeline.com/apexonco/novartis-calls-time-tim-3-and-hif2a ESMO 2025 preview – first clinical results | ApexOnco - Oncology Pipeline, accessed April 25, 2026, https://www.oncologypipeline.com/apexonco/esmo-2025-preview-first-clinical-results Emerging Therapeutic Approaches to Engage the Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer - MDPI, accessed April 24, 2026, https://www.mdpi.com/2072-6694/17/23/3755 Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer - PubMed, accessed April 24, 2026, https://pubmed.ncbi.nlm.nih.gov/39293515/ Prostate Cancer Pipeline, Therapies, Companies, and MOA - DelveInsight, accessed April 24, 2026, https://www.delveinsight.com/report-store/prostate-cancer-competitive-landscape ASCO 2023: A Quick Preview on Antibody-drug Conjugate Abstracts - DelveInsight, accessed April 24, 2026, https://www.delveinsight.com/asco-conference/article/asco-2023-adc-preview Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting, accessed April 25, 2026, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-advances-bold-vision-future-cancer-care-asco-2025 Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026, accessed April 25, 2026, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-showcases-oncology-innovation-and-next-generation Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 - BioSpace, accessed April 24, 2026, https://www.biospace.com/press-releases/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026 Mesothelioma Drug Pipeline — PatSnap Eureka, accessed April 25, 2026, https://www.patsnap.com/resources/blog/ls-blog/mesothelioma-drug-pipeline-patsnap-eureka/ Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025, accessed April 25, 2026, https://nonabio.com/nona-biosciences-partner-pfizer-presents-preclinical-data-on-top1i-based-adc-targeting-msln-at-aacr-annual-meeting-2025/ Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting, accessed April 25, 2026, https://nonabio.com/nona-biosciences-collaboration-partner-pfizer-announces-presentation-of-phase-1-clinical-study-design-on-mesoc2-an-msln-targeting-adc-at-the-2025-asco-annual-meeting/ Development to Discontinue for ZW171 in Gynecologic, Thoracic, and GI Cancer | OncLive, accessed April 25, 2026, https://www.onclive.com/view/development-to-discontinue-for-zw171-in-gynecologic-thoracic-and-gi-cancer Top 10 ADC Companies Driving Innovation - Roots Analysis, accessed April 25, 2026 https://www.rootsanalysis.com/key-insights/top-10-adc-companies.html

2025-12-29

·bilibili

MSLN 靶向：阿麦妥单抗（Amatuximab）的实体瘤治疗与科研价值

MSLN（间皮素，mesothelin）是一种细胞表面糖蛋白，主要表达于胸膜、腹膜、心包膜等间皮组织及部分上皮源性肿瘤细胞表面，在恶性胸膜间皮瘤、胰腺癌、卵巢癌、肺癌等实体瘤中呈现高特异性过表达，而在正常成人组织中仅低水平限制性表达。这种肿瘤特异性表达特征，使其成为实体瘤精准靶向治疗的重要靶点。生理状态下，MSLN 参与细胞黏附与信号传导；在病理场景中，其异常高表达会促进肿瘤细胞增殖、侵袭、转移及血管生成，同时参与肿瘤免疫微环境的免疫抑制调控，与肿瘤的恶性进展及不良预后密切相关，是实体瘤治疗的关键分子靶点。阿麦妥单抗（Amatuximab，研发代号 MORAb-009）是一款靶向 MSLN 的嵌合型单克隆抗体（IgG1 亚型），核心优势在于对 MSLN 抗原的高特异性识别与高亲和力结合 —— 通过抗体可变区精准锚定肿瘤细胞表面的 MSLN，一方面可通过抗体依赖的细胞毒性（ADCC）和补体依赖的细胞毒性（CDC），激活机体免疫细胞特异性杀伤肿瘤细胞；另一方面，其抗体骨架可作为靶向递送载体，偶联细胞毒性药物、放射性核素或免疫毒素，构建成抗体药物偶联物（ADC）、靶向放射性药物等，实现 “精准靶向 + 强效杀伤” 的协同功效，尤其在恶性胸膜间皮瘤等难治性实体瘤治疗中展现出独特潜力。作为 MSLN 靶向治疗的代表性药物，阿麦妥单抗的研发历程聚焦于恶性胸膜间皮瘤这一罕见且预后极差的实体瘤。临床研究显示，其单药治疗晚期恶性胸膜间皮瘤患者，能有效稳定肿瘤病灶，缓解胸痛、呼吸困难等肿瘤相关症状，为化疗耐药或无法耐受化疗的患者提供了低毒的治疗选择；与化疗药物联用后，可显著提升化疗的抗肿瘤效果，降低化疗对正常组织的毒副作用，延长患者无进展生存期与总生存期。此外，针对胰腺癌、卵巢癌等 MSLN 阳性实体瘤的临床前研究也证实，阿麦妥单抗能有效抑制肿瘤细胞增殖与转移，为其适应症拓展奠定了基础。近年来，随着精准治疗与联合治疗技术的发展，阿麦妥单抗的科研价值被进一步挖掘。在联合治疗策略中，科研人员发现其与免疫检查点抑制剂联用，可通过靶向清除 MSLN 阳性肿瘤细胞、打破肿瘤免疫抑制微环境，提升实体瘤患者的免疫治疗应答率；与抗血管生成药物联用，能协同抑制肿瘤血管生成与细胞增殖，进一步遏制肿瘤进展，相关临床前研究已展现出显著的协同效应。在药物创新层面，阿麦妥单抗的靶向特性为新一代 MSLN 靶向药物研发提供了重要参考。科研人员基于其结合表位，优化抗体结构（如人源化改造、提升内化效率），探索与新型细胞毒载荷（如 DNA 拓扑异构酶 Ⅰ 抑制剂、微管抑制剂）的偶联应用，开发出疗效更优、安全性更高的 ADC 药物；此外，阿麦妥单抗也为双特异性抗体的设计提供了思路，通过构建 MSLN/CD3、MSLN/PD-L1 双靶点抗体，同时激活 T 细胞免疫与靶向杀伤肿瘤细胞，为复发难治性实体瘤提供了新的治疗方向。在科研领域，科研级阿麦妥单抗（型号 TKYR1028）凭借高纯度（≥95%）、高特异性及稳定的生物学活性，成为核心研究工具。其广泛应用于MSLN 靶点验证、实体瘤细胞增殖与侵袭机制研究、靶向药物特异性评价、肿瘤动物模型构建等场景。例如，在恶性胸膜间皮瘤机制研究中，可通过阿麦妥单抗阻断 MSLN，明确其对肿瘤细胞上皮 - 间质转化（EMT）及免疫逃逸的调控作用；在靶向药物研发中，其可作为阳性对照，验证候选药物的靶向结合能力与抗肿瘤活性。随着实体瘤精准靶向治疗技术的持续迭代，MSLN 靶点的临床价值与科研潜力持续释放。泰克生物依托成熟的重组抗体研发平台与丰富的靶向药物研究经验，推出科研级阿麦妥单抗（TKYR1028），产品严格遵循科研标准，精准匹配 MSLN 相关科研需求，助力科研工作者在实体瘤机制研究、新型靶向疗法研发中高效突破。

抗体药物偶联物免疫疗法放射疗法

100 项与 Amatuximab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09767	Amatuximab	-	DB12845

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不可切除的胸膜恶性间皮瘤	临床2期	美国	Morphotek, Inc.	2015-11-03
不可切除的胸膜恶性间皮瘤	临床2期	澳大利亚	Morphotek, Inc.	2015-11-03
不可切除的胸膜恶性间皮瘤	临床2期	法国	Morphotek, Inc.	2015-11-03
不可切除的胸膜恶性间皮瘤	临床2期	德国	Morphotek, Inc.	2015-11-03
不可切除的胸膜恶性间皮瘤	临床2期	意大利	Morphotek, Inc.	2015-11-03
不可切除的胸膜恶性间皮瘤	临床2期	英国	Morphotek, Inc.	2015-11-03
恶性胸膜间皮瘤	临床2期	加拿大	Morphotek, Inc.	2008-12-31
恶性胸膜间皮瘤	临床2期	荷兰	Morphotek, Inc.	2008-12-31
恶性胸膜间皮瘤	临床2期	西班牙	Morphotek, Inc.	2008-12-31
胰腺腺癌	临床2期	美国	Morphotek, Inc.	2007-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00738582 (Amatuximab, CTgov)	临床2期	恶性胸膜间皮瘤	89	amatuximab+pemetrexed+cisplatin (All Participants)	鬱獵觸襯醖築壓鑰壓膚 = 鏇觸艱膚襯繭願衊鹽衊鬱鹽積壓糧窪壓襯衊糧 (蓋製醖膚憲襯憲糧鏇鑰, 選廠築遞壓夢衊糧網鏇 ~ 憲蓋衊製範積簾鑰簾構) 更多	-	2022-09-22
NCT00738582 (Amatuximab, CTgov)	临床2期	恶性胸膜间皮瘤	89	Amatuximab+Pemetrexed+Cisplatin (Amatuximab/Pemetrexed/Cisplatin)	醖範壓顧繭糧膚鑰糧積(鹹糧積範觸廠鏇鏇壓鹽) = 艱積夢膚網範淵鹹襯淵簾簾遞簾襯憲淵顧餘觸 (醖艱窪積構鑰築襯獵鏇, 蓋餘願齋選醖憲製觸襯 ~ 範築製鏇艱壓鹽醖鹹顧) 更多	-	2022-09-22
NCT02357147 (ARTEMIS, CTgov)	临床2期	不可切除的胸膜恶性间皮瘤	124	Amatuximab+Pemetrexed+Cisplatin (Combination Treatment Phase:Amatuximab + Pemetrexed +Cisplatin)	簾鏇壓淵壓顧願壓廠獵 = 衊積願蓋製鑰淵顧選糧齋廠築鏇憲餘鏇夢選鬱 (襯鹽網壓艱淵蓋簾鹽範, 艱網範餘膚廠壓憲齋遞 ~ 鏇遞夢廠範積糧鑰淵願) 更多	-	2020-03-17
NCT02357147 (ARTEMIS, CTgov)	临床2期	不可切除的胸膜恶性间皮瘤	124	Placebo+Pemetrexed+Cisplatin (Combination Treatment Phase: Placebo + Pemetrexed + Cisplatin)	簾鏇壓淵壓顧願壓廠獵 = 遞顧鏇齋鹽糧觸憲繭鏇齋廠築鏇憲餘鏇夢選鬱 (襯鹽網壓艱淵蓋簾鹽範, 壓廠鹽餘鏇醖憲夢襯範 ~ 遞憲蓋膚窪鹽壓選襯網) 更多	-	2020-03-17
NCT02357147 (ASCO2016)	临床2期	恶性胸膜间皮瘤	560	Amatuximab + P/C	構鏇醖選觸顧築壓觸獵(糧獵構顧壓齋鹽範鏇觸) = 鹹齋鹽糧製醖構憲積範餘顧簾膚膚網壓獵蓋願 (鏇築窪齋憲製夢獵淵齋 )	-	2016-05-20
NCT01018784 (Pubmed \| Invest New Drugs)	临床1期	晚期恶性实体瘤	17	Amatuximab	鏇壓範範齋遞齋鹹鏇範(網餘網簾遞顧鹽鬱蓋窪) = 遞範襯願膚憲製顧鏇網鹹顧鬱顧獵窪觸鬱鏇鬱 (製範淵鬱選窪選壓艱艱 ) 更多	-	2015-04-01
WCLC2013	N/A	不可切除的胸膜恶性间皮瘤	89	Amatuximab 5mg/kg	獵蓋網壓鹹築齋積衊蓋(範襯窪壓醖構選憲齋餘) = 築醖窪繭願齋壓衊範衊構製鑰膚鹹襯簾夢窪醖 (淵憲膚願糧鏇膚選襯壓 ) 更多	-	2013-10-29
ASCO2012	临床2期	不可切除的胸膜恶性间皮瘤	89	Amatuximab + Pemetrexed + Cisplatin	構餘壓糧構簾選鹹願築(蓋壓構顧願襯遞醖鏇願) = 衊製鹽繭製獵餘窪襯獵遞淵蓋鏇構構鬱繭觸簾 (窪遞憲鹹鏇艱觸構選構 ) 更多	-	2012-05-20
NCT00570713 (CTgov)	临床2期	胰腺腺癌 \| 不能切除性胰腺癌 \| 胰腺癌	155	MORAb-009+Gemcitabine (MORAb-009 Plus Gemcitabine ('MORAb-009'))	艱餘廠選鬱獵艱構夢憲(蓋簾餘廠製觸壓齋選願) = 蓋願蓋糧餘選蓋鏇遞鹽艱簾選鹹憲夢壓艱願膚 (願積鹽醖繭鑰觸觸繭齋, 鑰淵鹽窪簾鬱鑰淵顧夢 ~ 餘觸構膚積鹹遞醖餘觸) 更多	-	2012-03-27
NCT00570713 (CTgov)	临床2期	胰腺腺癌 \| 不能切除性胰腺癌 \| 胰腺癌	155	Placebo+Gemcitabine (Placebo Plus Gemcitabine ('Placebo'))	艱餘廠選鬱獵艱構夢憲(蓋簾餘廠製觸壓齋選願) = 簾願襯網憲廠簾餘餘夢艱簾選鹹憲夢壓艱願膚 (願積鹽醖繭鑰觸觸繭齋, 淵艱範夢顧製憲獵廠構 ~ 築觸範積蓋願積衊衊憲) 更多	-	2012-03-27